Radioimmunotherapy with <sup>177</sup>Lu-DOTA-Rituximab: Final Results of a Phase I/II Study in 31 Patients with Relapsing Follicular, Mantle Cell, and Other Indolent B-Cell Lymphomas - Concepedia

Concepedia

Publication | Open Access

Radioimmunotherapy with <sup>177</sup>Lu-DOTA-Rituximab: Final Results of a Phase I/II Study in 31 Patients with Relapsing Follicular, Mantle Cell, and Other Indolent B-Cell Lymphomas

DOI Full Paper Access

56

Citations

34

References

2013

Year

Flavio Forrer, Catharina Oechslin-Oberholzer, Benedetta Campana, Richard Herrmann, Helmut R. Maëcke, Jan Mueller‐Brand, Andreas Lohri

Journal of Nuclear Medicine

Abstract

Our results demonstrate the safety and feasibility of (177)Lu-DOTA-rituximab treatment for the lymphoma entities tested in this study.

References

	Year	Citations

Page 1